AstraZeneca Secures Global Rights to Lung Cancer Therapy in $600m Deal (AZN)
Medical research ©National Institutes of Health AstraZeneca (LSE:AZN) has agreed to pay Chinese biotechnology company Dizal Pharmaceutical $600…
Browsing Tag